^
    Back
    Association details:
    Biomarker:FLT3 F691L
    Cancer:Acute Myelogenous Leukemia
    Drug:crenolanib (ARO-002) (FLT3 inhibitor, PDGFR α inhibitor, PDGFR β inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2020
    Title:

    Clinical Benefit of Crenolanib, with or without Salvage Chemotherapy, in Multiply Relapsed, FLT3 Mutant AML Patients after Prior Treatment with Gilteritinib

    Published date:
    11/04/2020
    Excerpt:
    The pt with FLT3-F691 mutation and cranial nerve palsy due to CNS leukemia had clearance of CNS blasts and improvement in cranial nerve function after HIDAC, crenolanib, and intrathecal cytarabine; this patient achieved morphologic leukemia free state and FLT3 negativity in the BM.
    Secondary therapy:
    cytarabine
    DOI:
    https://doi.org/10.1182/blood-2020-139898